Synaptic Agent Fosgonimeton Falls Short in Phase 2/3 LIFT-AD Trial of Mild-to-Moderate Alzheimer Disease

Published Date: 05 Sep 2024

Despite failing to meet its primary end point, fosgonimeton showed greater numerical treatment effect in patients with more advanced disease, as well as those who were APOE e4 carriers.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The Boom in ADHD Coaching Has Few Rules

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

4.

Medicaid expansion tied to smaller declines in early-stage cancer detection

5.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot